Abstract
Palliative chemotherapy in advanced colorectal cancer prolongs survival and maintains quality of life compared with best supportive care alone. Campto® is indicated for use, in either first-line treatment in combination with fluorouracil (5-FU) and folinic acid or second-line monotherapy. Results from three multi-centred randomized trials, have shown that Campto provides clinically relevant and statistically significantly improved response rates, time to progression and survival vs 5-FU/folinic acid alone or best supportive care, while maintaining the quality of life in patients with advanced colorectal cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
